This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a full
At ESC 2022, a palpable hush preceded the surprising results, which are likely to leave in place current guidelines for heart failure and revascularization.